LQCL2208 - CMLE - GIANT PROERYTHROBLASTS: PARVOVIRUS B19 ASSOCIATED PURE RED CELL APLASIA IN A KIDNEY TRANSPLANT PATIENT-GIANT PROERYTHROBLASTS: PARVOVIRUS B19 ASSOCIATED PURE RED CELL APLASIA IN A KIDNEY TRANSPLANT PATIENT

GIANT PROERYTHROBLASTS: PARVOVIRUS B19 ASSOCIATED PURE RED CELL APLASIA IN A KIDNEY TRANSPLANT PATIENT

Pdf Summary

The document discusses a case study of a 46-year-old man post-kidney transplant with severe anemia due to parvovirus B19-associated pure red cell aplasia (PRCA). The patient presented with symptoms of anemia and a significant decrease in erythroid precursors in the bone marrow confirmed by bone marrow biopsy. Laboratory tests, including PCR, showed high levels of parvovirus B19. Treatment involved intravenous immunoglobulin therapy and reduction in immunosuppressive therapy, leading to a rapid improvement in the patient's condition. The text emphasizes the importance of early recognition of PRCA caused by parvovirus B19, proper diagnostic testing, and prompt treatment initiation. Management recommendations include high-dose IVIG and supportive care with blood products until red blood cell production improves. The document also outlines key learning objectives related to laboratory values, morphological characteristics, ancillary testing, and treatment modalities for parvovirus B19-associated PRCA. Laboratory technicians are advised to promptly communicate atypical findings to pathologists for timely diagnosis and treatment planning to reduce patient hospital stays and healthcare costs. In summary, the case study underscores the significance of considering parvovirus B19 infection in immunocompromised patients with progressive anemia and PRCA and highlights the importance of appropriate diagnostic testing and early intervention in managing this condition.

Keywords

kidney transplant

severe anemia

parvovirus B19

pure red cell aplasia

bone marrow biopsy

intravenous immunoglobulin therapy

immunosuppressive therapy

early recognition

diagnostic testing

treatment initiation